Literature DB >> 33900006

Prognostic significance of carcinoembryonic antigen combined with carbohydrate antigen 19-9 following neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer.

Zhifang Zheng1,2, Xiaojie Wang1,2, Xingrong Lu1,2, Ying Huang1,2, Pan Chi1,2.   

Abstract

AIM: The clinical significance of carcinoembryonic antigen (CEA) combined with carbohydrate antigen 19-9 (CA19-9) in patients with rectal cancer is not well established. The aim of this study was to determine the prognostic value of these combined tumour markers in patients with locally advanced rectal cancer (LARC) treated with neoadjuvant chemoradiotherapy (nCRT).
METHODS: A total of 687 consecutive patients with LARC who underwent nCRT and radical surgery were analyzed. Tumour characteristics, recurrence-free survival (RFS) and overall survival (OS) were compared according to the number of elevated tumour markers measured before and after nCRT. In addition, the prognostic significance of perioperative changes in the combined tumour markers was further evaluated. RESULT: The RFS and OS rates decreased in a stepwise manner in association with the number of elevated pre- and post-nCRT tumour markers (all P<0.05). Multivariate analysis showed that only the number of elevated post-nCRT tumour markers was an independent prognostic factor (both P<0.05). For 311 patients with elevated pre-nCRT tumour markers, normalization of the tumour markers after nCRT was an independent prognostic protective factor (both P<0.05), and patients with both markers elevated post-nCRT had a 2.5-fold and 3.7-fold increased risk of recurrence and death, respectively (P<0.05). Furthermore, normalization of post-nCRT tumour markers after surgery was also closely related to improved prognosis.
CONCLUSION: This combination of post-nCRT tumour markers can accurately predict the long-term survival of patients with LARC treated with nCRT and curative resection, and the normalization of the combined tumour markers after either nCRT or surgery was associated with better survival. This article is protected by copyright. All rights reserved.

Entities:  

Keywords:  carbohydrate antigen 19-9; carcinoembryonic antigen; neoadjuvant chemoradiotherapy; rectal cancer; survival

Year:  2021        PMID: 33900006     DOI: 10.1111/codi.15694

Source DB:  PubMed          Journal:  Colorectal Dis        ISSN: 1462-8910            Impact factor:   3.788


  2 in total

1.  C-Reactive Protein as Predictive Biomarker for Response to Chemoradiotherapy in Patients with Locally Advanced Rectal Cancer: A Retrospective Study.

Authors:  Fátima Aires; Darlene Rodrigues; María Piñeiro Lamas; Maria Teresa Herdeiro; Adolfo Figueiras; Maria José Oliveira; Margarida Marques; Ana Teresa Pinto
Journal:  Cancers (Basel)       Date:  2022-01-19       Impact factor: 6.639

2.  The number of cycles of adjuvant chemotherapy in stage III and high-risk stage II rectal cancer: a nomogram and recursive partitioning analysis.

Authors:  Wei-Wei Chen; Wen-Ling Wang; Hong-Min Dong; Gang Wang; Xiao-Kai Li; Guo-Dong Li; Wang-Hua Chen; Juan Chen; Sai-Xi Bai
Journal:  World J Surg Oncol       Date:  2022-04-12       Impact factor: 2.754

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.